Journal
GYNECOLOGIC ONCOLOGY
Volume 133, Issue 3, Pages 427-432Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2014.03.576
Keywords
Ovarian cancer; Platinum-refractory; Platinum-resistant; Targeted chemotherapy; LHRH receptor targeted
Categories
Ask authors/readers for more resources
Objectives. To evaluate the activity and toxicity of AEZS-108 (Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors. Methods. Women with epithelial ovarian, fallopian tube or primary peritoneal cancer, expressing LHRH receptors were eligible for this trial, when they had progression during treatment with a platinum based regimen or within 6 months after receiving a platinum based regimen and a previous taxane treatment At least one measurable target lesion (RECIST) or CA-125 levels higher than twice the upper limit of normal range (GCIG-criteria) were required. Patients received AEZS-108 (267 mg/m(2) equimolar to 76.8 mg/m(2) of free doxorubicin) every 3 weeks as a two hour i.v. infusion. Results. Fifty-five of 59 (93%) of ovarian cancer samples screened expressed LHRH receptors. 42 patients were enrolled in this study and received at least 1 infusion of AEZS-108 (ITT population). Of these 42 patients 6 (143%) had a partial response, 16 (38%) stable disease, 16 (38%) progressive disease and 4 patients were not evaluable. Median time to progression was 12 weeks (95% CI: 8-20 weeks), and median overall survival was 53 weeks (95% CI: 39-73 weeks). Toxicity profile was favorable. Conclusion. AEZS-108 has a clinical activity in platinum refractory/resistant ovarian cancer which, seems to be comparable to that of pegylated liposomal doxorubicin or to topotecan. Toxicity was comparably low. These data support the concept of a targeted chemotherapy for tumors expressing LHRH receptors. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available